About Contact Us Careers

Sickle Cell Disease Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3094
Published Date: Sep 02, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Sickle Cell Disease Drugs Landscape

Addmedica SAS
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Medunik USA Inc.
Emmaus Life Sciences, Inc.
CellSeed, Inc.
Global Blood Therapeutics, Inc.
Sio Gene Therapies Ltd.
Imara, Inc.
Modus Therapeutics AB
Bluebird bio, Inc.
Vertex Pharmaceuticals Incorporated

Browse Key Market Insights with Data Illustration:

Sickle Cell Disease Drugs Market Size & Share, Growth Analysis 2036

In the News

· April 20, 2021: Bluebird Bio, Inc. announced the updated status of its undertrial drug LentiGlobin for sickle cell disease, which is in its Phase 1/2 study.

Author Credits: Radhika Pawar

Report ID: 3094
Published Date: Sep 02, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of sickle cell disease drugs is evaluated at USD 3.05 billion.

Sickle Cell Disease Drugs Market size was over USD 2.71 billion in 2023 and is poised to cross USD 18.45 billion by 2036, growing at more than 15.9% CAGR during the forecast period i.e., between 2024-2036. Rising prevalence of sickle cell disease, such as, sickle cell anemia, due to genetic mutation will boost the market growth.

North America is anticipated to account for largest revenue share by 2036, on the back of advanced medical facilities, and research and development activities.

The major players in the market are Medunik USA Inc., Emmaus Life Sciences, Inc., CellSeed, Inc., Global Blood Therapeutics, Inc., Sio Gene Therapies Ltd., Imara, Inc., Modus Therapeutics AB, Bluebird bio, Inc., Vertex Pharmaceuticals Incorporated, and others.

Inquiry Before Buying Request Free Sample